First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes Clinical Trial

Official title:

An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05086315
• Other study ID #: TCD17197
• Secondary ID: U1111-1266-73992
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 8, 2021
• Est. completion date: November 11, 2026

Study information

• Verified date: May 2024
• Source: Sanofi
• Contact: Trial Transparency email recommended (Toll free for US & Canada)
• Phone: 800-633-1610
• Email: Contact-US[@]sanofi.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

Description:

2.5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 126
• Est. completion date: November 11, 2026
• Est. primary completion date: December 11, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• Participant must be at least 1 year old at the time the trial participant or legal

guardian signs the informed consent form and will be assigned as follows:

• Adult arm: aged at least 12 years old.
• Pediatric arm: aged 1 to 17 years old.

For participants of the Escalation Part only:

• Adult and Pediatric Arms: Confirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL) and juvenile myelomonocytic leukemia (JMML)] according to World Health Organization (WHO) 2022 classification. Participants with AML must meet one of the following criteria, a), b), c) or d) and are limited to those with no available (or are ineligible) therapy with known clinical benefit. a) Primary Induction Failure (PIF) AML, defined as disease refractory to one of the following, i or ii. i) An intensive induction attempt, per institution. Induction attempts include high-dose and/or standard-dose cytarabine ± an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth factor or targeted therapy containing regimens.

Examples include but are not limited to:

• One cycle of high dose cytarabine (HiDAC) containing regimen
• One cycle of liposomal cytarabine and daunorubicin
• Two cycles of standard dose cytarabine containing regimen ii) For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens, 1 or 2: 1. 4 cycles of hypomethylating agents (HMA) or

2. 2 cycles HMA + venetoclax b) Early relapse (ER) AML, defined as AML in relapse with CR duration < 6 months on prior induction treatment c) Leukemia in first or higher relapse d) For participants aged 1 to 17 years old, primary induction failure is defined as disease refractory after two cycles of induction therapy.

• Adult arm only: Confirmed diagnosis of cluster of differentiation 123 (CD123) + HR-MDS, with a Revised International Prognostic Scoring System (IPSS-R) risk category of intermediate or higher and are limited to those with no available (or are ineligible) therapy with known clinical benefit.
• Not eligible for induction therapy and having completed =2 cycles of any of the following: hypomethylating agent (eg, 5 azacitidine or decitabine) and/or venetoclax, chemotherapy, or targeted agents.
• Not eligible for autologous stem cell transplant (ASCT) and having completed =1 course of induction therapy.
• Adult and Pediatric arms and escalation part only: Confirmed diagnosis of CD123+ B-ALL without extramedullary lesions that have no available (or are ineligible) therapy with known clinical benefit.

For Participants in the Expansion Part Only (Adults only):

• For participants in Cohort A: Participants meeting inclusion criteria for AML participants that have been primary refractory (PIF) to prior induction treatment or who have had ER occurring 6 months or less after an initial remission on prior induction treatment.
• For participants in Cohort B: Participants meeting inclusion criteria for AML participants that have had late relapse (LR), occurring more than 6 months after an initial remission on prior induction treatment.
• Body weight at least 10 kg.
• Pediatric arm and escalation part only: Confirmed diagnosis of BPDCN according to World Health Organization (WHO) 2022 classification, who have relapsed or refractory disease with no available (or are ineligible) therapy with known clinical benefit.
• Pediatric arm and expansion part only: For participants in Cohort C: Participants with AML who have relapsed according to inclusion criteria for AML or have recurrent disease resistant or intolerant to available therapies.

Exclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status >2 (=18 years-old). Karnovsky Scale (16-17 years-old) <50% or Lansky Scale (<16 years-old) <50%.
• Ongoing or recent (within 5 years) evidence of significant autoimmune disease that requires or required treatment with systemic immunosuppressive treatments, which may suggest a risk for immune-related adverse events. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that required only hormone replacement or psoriasis that does not require systemic treatment.
• History of an invasive malignancy that requires active therapy (adjuvant hormonal therapy is allowed) other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
• Evidence of active central nervous system leukemia at the time of enrollment as evidenced by cytology or pathology. Except for participants aged 1 to 17 years, central nervous system 1 disease (CNS1) and CNS2 disease are allowed.
• Known acquired immunodeficiency syndrome (AIDS-related illnesses) or human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or having active hepatitis B or C infection, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
• Prior treatment with an anti-CD123-directed agent (except for participants with BPDCN in the pediatric arm).
• Prior HSCT with relapse beyond 3 months or prior CAR-T therapy in B-ALL with relapse beyond 2 months may be included only if off immunosuppression for a minimum of 4 weeks and no evidence of graft-versus-host disease (GVHD).
• Receiving at the time of first investigational medicinal product (IMP) administration corticosteroid as a concomitant medication with corticosteroid dose >10 mg/day of oral prednisone or the equivalent,
• AML, BPDCN, or HR-MDS participants with prior treatment with cellular therapy, eg, chimeric antigen receptor T cell (CAR-T) or chimeric antigen receptor NK cell (CAR-NK). Prior CAR-T therapy is allowed for participants with B-ALL.
• Concurrent treatment with other investigational drugs.
• Radiotherapy, even if palliative in intent, may not be given during the study.
• Prophylactic use of hematopoietic growth factors (eg, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin) during the DLT observation period in the Dose Escalation Part only. - Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
• Pregnant and breast-feeding women.
• History of solid organ transplant, including corneal transplant.
• Average QTc (using the Fridericia correction calculation) greater than 470 milliseconds (msec) at screening. For pediatric arm participants only, inadequate ejection fraction as per institutional standards at screening or any clinically significant cardiac conditions (including but not limited to congestive heart failure, myocarditis, pericarditis, arrythmias).
• Pediatric arm only: Participants with known inherited bone marrow failure syndromes (e.g., bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome). Participants with Down syndrome with adequate organ function as per Investigator discretion are allowed to participate in the study. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related Conditions & MeSH terms

• Acute Lymphocytic Leukaemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Neoplasms
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• SAR443579
Powder for solution for infusion; by IV infusion

Locations

Country	Name	City	State
Australia	Investigational Site Number :0360001	Melbourne	Victoria
Australia	Investigational Site Number :0360002	Melbourne	Victoria
China	Investigational Site Number : 1560001	Tianjin
China	Investigational Site Number : 1560003	Zhengzhou
France	Investigational Site Number :2500002	Marseille
France	Investigational Site Number : 2500004	Paris
France	Investigational Site Number :2500001	Paris
France	Investigational Site Number :2500003	Villejuif
Netherlands	Investigational Site Number :5280002	Amsterdam
Netherlands	Investigational Site Number :5280003	Groningen
Netherlands	Investigational Site Number : 5280005	Nijmegen
Netherlands	Investigational Site Number :5280001	Rotterdam
Netherlands	Investigational Site Number :5280004	Utrecht
United States	Emory University-Site Number:8400006	Atlanta	Georgia
United States	Beth Israel Deaconess Medical Center-Site Number:8400004	Boston	Massachusetts
United States	Montefiore Medical Center-Site Number:8400012	Bronx	New York
United States	The Ohio State University Comprehensive Cancer Center Site Number : 8400009	Columbus	Ohio
United States	City of Hope-Site Number:8400002	Duarte	California
United States	MD Anderson Cancer Center-Site Number:8400001	Houston	Texas
United States	Weill Cornell Medical College-Site Number:8400003	New York	New York
United States	Children's Hospital of Philadelphia-3401 Civic Center Blvd Site Number : 8400013	Philadelphia	Pennsylvania
United States	Oregon Health and Science University-Site Number:8400011	Portland	Oregon
United States	Seattle Childrens Hospital and Regional Medical Center Site Number : 8400014	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Australia,  China,  France,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicity (DLT) (Escalation Part)		Day 1 to Day 28
Primary	Proportion of participants who have a CR (Complete Remission) + CRi (Complete Remission with Incomplete Hematological Recovery) (Expansion Part)		Up to 6 months
Secondary	Recommended Dose for Expansion (RDE)		Up to 12 months
Secondary	Number of participants with treatment-emergent adverse events (TEAEs) (Escalation and Expansion Parts)		Up to 30 months
Secondary	Cmax: Maximum observed concentration		Day 1 to end of trial (maximum up to 30 months)
Secondary	Incidence of anti-drug antibody (ADA) (Escalation and Expansion Parts)		Up to 30 months
Secondary	Anti-leukemic activity as define by International Working Group (IWG) for AML (modified) and MDS, or National Comprehensive Cancer Network (NCCN) for B-ALL (Escalation Part)		Up to 6 months
Secondary	Proportion of participants with CR + complete remission with partial hematological recovery (CRh) (Expansion Part)		Up to 6 months
Secondary	Rate of CR + CRh + CRi + morphological leukemia-free state (MLFS) (Expansion Part)		Up to 6 months
Secondary	Time interval from first documented evidence of Composite Complete Remission (CRc: (CR or CRi)) until disease relapse as per modified IWG or death due to any cause, whichever comes first (Expansion Part)		Up to 30 months
Secondary	Time from the first documented evidence of CR or CRh until disease relapse or death due to any cause, whichever comes first (Expansion Part)		Up to 30 months
Secondary	Time from the first documented evidence of CR or CRi or CRh or MLFS until disease relapse or death due to any cause, whichever comes first (Expansion Part)		Up to 30 months
Secondary	Time interval from the first SAR443579 administration to the date of earliest evidence of relapse, treatment failure, or death (Expansion Part)		Up to 30 months
Secondary	Proportion of survivors from the first SAR443579 administration to death from any cause (Expansion Part)		Up to 12 months
Secondary	Rate of hematopoietic stem cell transplantation (HSCT) through SAR443579 treatment but before subsequent therapy (Expansion Part)		Up to 30 months
Secondary	Time from first SAR443579 administration to discontinuation for any reason excluding remission, ie, disease progression/disease relapse, treatment toxicity, participant preference or death (Expansion Part)		Up to 30 months
Secondary	Time from first SAR443579 administration to death due to any cause		Up to 30 months